Corporate Symposia

Corporate Symposia

The following programs are planned and conducted by the corporate community in conjunction with AADE16. They provide attendees with additional education and information opportunities. Program content and product information are the sole responsibility of the corporate supporters. The first 30 minutes of each symposium will consist of a buffet dinner. 1.5 CE available per session. In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this educational program is limited to health care professionals. Accordingly, attendance by guests or spouses is not appropriate and cannot be accommodated.

All events held at the Marriott Marquis Hotel. Doors will open 30 minutes before scheduled start time.
NEW! Seating is first come, first serve.

Sunday, Aug. 14 6:00 pm – 8:00 pm

CS01 Achieving Partnerships and Improving Outcomes in Your Diabetes Patients

Marriott Marquis Hotel, Pacific Ballroom 18, North Tower, Level 1
Supported by an unrestricted educational grant provided by AstraZeneca

Learning Objectives

  1. Describe the latest standards of care for type 2 diabetes
  2. List strategies for patient education and engagement
  3. Describe evidence for the use of early and intensive combination treatment

This live program, presented by a panel of three key opinion leaders, will provide participants with an understanding of the latest standards of care for type 2 diabetes, including strategies for patient education and engagement, and evidence for the use of early and intensive combination treatment. The live activity allows for significant audience interaction to bring issues and questions to the forefront of the discussion and deepens participant involvement.

Joshua J. Neumiller, PharmD, CDE, FASCP, Associate Professor, Washington State University
Virginia Valentine, APRN-CNS, BC-ADM, CDE, FAADE, Clinical Nurse Specialist, Sage Specialty Care
Sandra Bollinger, PharmD, CDE, President/Owner, Health Priorities, Inc.

CS02 Constructing an Open and Shut Case for the Practical Application of New Insulin Formulations in Type 2 Diabetes

Marriott Marquis Hotel, Pacific Ballroom 25, North Tower, Level 1
Supported by an unrestricted educational grant provided by Novo Nordisk

Learning Objectives

  1. Compare and Contrast the therapeutic characteristics, efficacy, and safety of long-acting vs. ultralong-acting basal insulins.
  2. Calculate appropriate doses for initiating and titrating ultralong-acting basal, and for switching between different types of insulin.
  3. Individually intensify long-or ultralong-acting basal insulin therapy using p randial insulin or a GLP-1 RA including premixed or co-formulated agents in patients with T2DM.

This live activity will provide diabetes educators (DEs) with expert perspectives on current and emerging evidence about new treatment options for type 2 diabetes mellitus (T2DM), As the program title implies, the lively, “shut-the-box” game-based format will use lectures and realistic clinical cases to present expert perspectives on data and practical information relevant to the newly approved ultralong-acting insulins and how to use them. Data for emerging coformulations of basal insulin with GLP-1 RAs will also be reviewed.

Debbie Hinnen, APRN, BC-ADM, CDE, FAAN, FAADE, Advanced Practice Nurse, Memorial Hospital, University of Colorado Health System (Program Chair)
Daniel Einhorn, MD, FACP, FACE, Medical Director, Scripps Whittier Diabetes Institute
John Sink, PA-C, CDE, CLS, MPAS, Physician Assistant, The Jones Center for Diabetes & Endocrine Wellness

CS03 Does the Shoe Fit? Matching the Right Insulin Combination to Individual Patients with T2DM

Mariott Marquis Hotel, Pacific Ballroom 21, North Tower, Level 1
Supported by an unrestricted educational grant provided by Sanofi

Learning Objectives

  1. Review criteria and indications for treatment intensification in patients with T2DM who are not achieving glycemic goals with oral antihyperglycemic agents alone.
  2. Assess the role of newer antihyperglycemic agents (GLP-1 RAs, DPP-4 inhibitors, and SGLT2 inhibitors) in complementary combination with insulin when managing T2DM across disease progress.
  3. Evaluate recent evidence regarding the use of insulin and GLP-1 RAs in complementary combinations across T2DM disease progression, including investigational fixed combinations or coformulations of insulin/GLP-1 RA

The content for this educational symposium is designed to provide participants with the ability to evaluate different antihyperglycemic therapy options that include complementary insulin combinations when treatment intensification is necessary in patients with T2DM.

Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner, Henry Ford Health System (Program Chair)
James R. Gavin III, MD, PhD, Chief Medical Officer and CEO, Healing Our Village, Inc.
Lucia M. Novak, MSN, APN-BC, BC-ADM, CDTC, Nurse Practitioner, Riverside Medical Associates

Social media & sharing icons powered by UltimatelySocial